About Contact Us Careers

Non-Hodgkin Lymphoma Therapeutics Market Size and Forecast, by Type of Therapy (Chemotherapy, Radiation Therapy, Target Therapy); Cell Type (B-Cell Lymphoma, T-Cell Lymphoma); Distribution Channel (Retail Pharmacies & Drug Stores, Hospital Pharmacies, Online Pharmacies) - Growth Trends, Key Players, Regional Analysis 2026-2035

  • Report ID: 5584
  • Published Date: Sep 16, 2025
  • Report Format: PDF, PPT

Non-Hodgkin Lymphoma Therapeutics Market Outlook:

Non-Hodgkin Lymphoma Therapeutics Market size was over USD 11.13 billion in 2025 and is anticipated to cross USD 22.94 billion by 2035, witnessing more than 7.5% CAGR during the forecast period i.e., between 2026-2035. In the year 2026, the industry size of non-hodgkin lymphoma therapeutics is assessed at USD 11.88 billion.

Non-Hodgkin Lymphoma Therapeutics Market Size
Discover Market Trends & Growth Opportunities: Request Free Sample PDF

The market’s growth is attributed to the increasing prevalence of non-hodgkin lymphoma. During the past few years, the world has witnessed a significant surge in the non-hodgkin lymphoma.

As per our survey, non-hodgkin lymphoma is amongst the most common hematological malignancy across the globe and accounts for about 3% of cancer deaths and diagnoses. Further, according to the American Cancer Society, there will be roughly 80,620 NHL diagnoses in 2024 (44,590 men and 36,030 women). This applies to both kids and adults.

Furthermore, there has been surge in research in this field in order to deal with the growing cases. For instance, Researchers funded by the NCI are improving our knowledge of lymphoma treatment. The lymph system, that's a component of the body's immune system, is the place where all lymphomas begin. Scientists are now able to create more individualized treatments for different subtypes of lymphoma owing to advances in understanding the gene alterations that might cause the disease. All this is leading to non-Hodgkin lymphoma therapeutics market growth.

Key Non-Hodgkin Lymphoma Therapeutics Market Insights Summary:

  • Regional Highlights:

    • North America non-hodgkin lymphoma therapeutics market will hold more than 30% share by 2035, fueled by adoption of AI and well-regulated frameworks in healthcare.

  • Segment Insights:

    • The chemotherapy segment in the non-hodgkin lymphoma therapeutics market is forecasted to achieve a 50% share by 2035, driven by chemotherapy's effectiveness, familiarity among healthcare practitioners, and cost advantages.
    • The hospital pharmacies segment in the non-hodgkin lymphoma therapeutics market is expected to achieve a 50% share by 2035, attributed to the increasing number of hospitals equipped for specialized treatments and comprehensive patient care.

  • Key Growth Trends:

    • Surge in geriatric population
    • Increasing health awareness amongst people

  • Major Challenges:

    • Limited Access to Treatment
    • Lack of efficient healthcare technology may hinder the non-hodgkin lymphoma therapeutics market’s revenue.

  • Key Players: Roche Holding AG, Bristol-Myers Squibb Company, Novartis AG, Pfizer Inc., Merck & Co., Inc., Gilead Sciences, Inc., Amgen Inc., Celgene Corporation (Bristol-Myers Squibb), AbbVie Inc., Takeda Pharmaceutical Company Limited.

Global Non-Hodgkin Lymphoma Therapeutics Market Forecast and Regional Outlook:

  • Market Size & Growth Projections:

    • 2025 Market Size: USD 11.13 billion
    • 2026 Market Size: USD 11.88 billion
    • Projected Market Size: USD 22.94 billion by 2035
    • Growth Forecasts: 7.5% CAGR (2026-2035)

  • Key Regional Dynamics:

    • Largest Region: North America (30% Share by 2035)
    • Fastest Growing Region: Asia Pacific
    • Dominating Countries: United States, Germany, Japan, United Kingdom, France
    • Emerging Countries: China, India, Japan, South Korea, Brazil

    • Last updated on : 16 September, 2025

Growth Drivers

  • Surge in geriatric population - According to the World Health Organization, one in six individuals globe are going to be 60 years of age or older by 2030. This will culminate in a rise in the proportion of people over 60 from 1 billion in 2020 to 1.4 billion at this point. At a median age of 67 years at diagnosis, non-hodgkin lymphoma (NHL) mostly impacts older persons.

Adults with NHL who are older may find treatment difficult. A decrease in functional reserve that is unique to each person as they age raises the possibility of treatment-related toxicity and death. Furthermore, the primary determinant of a patient's survival following a cancer diagnosis is their age. As a result, the demand for non-Hodgkin Lymphoma market is rising.

  • Increasing health awareness amongst people - People are becoming more conscious of their health, which leads to expectations that medicines will experience higher demand in near future. A number of health awareness programs are being organized by governments of various countries across the globe. The market is anticipated to respond in tandem with the novel drug introductions for the treatment of ovarian cancer. Various researchers are investing in the introduction of market-beneficial medications. More opportunities in the market result from this.
  • Rising number of R&D initiatives - Owing to the increased occurrence of these types of lymphomas, the non-hodgkin lymphoma therapeutics market is currently seeing the introduction of sophisticated products. Many significant market participants, both well-known and up-and-coming, have made investments in the creation of pipeline candidates and the introduction of new drugs.

The high number of patients with these tumors, who frequently need intensive and precise therapy because their symptoms don't show up, is the reason for the rising demand. Despite advanced diagnostics, the diagnosis of cancer in its latter stages is frequently made due to the absence of symptoms. Throughout the forecast period, this is anticipated to further fuel the market expansion for non-hodgkin lymphoma therapeutics. Therefore, the demand for more sophisticated treatments has resulted in rising R&D trends in the market.

Challenges

  • Limited Access to Treatment - The fact that most patients globally lack access to therapy is one of the biggest issues facing the sector. Almost every licensed medications for the treatment of non-hodgkin lymphoma are available in the majority of North American and European countries.

However, with developing and poor economies, there are few therapeutic choices available for the treatment of diseases. Although non-hodgkin lymphoma and other blood malignancies are highly prevalent in these nations, patients find it challenging to receive treatment on time due to a lack of available therapeutic alternatives.

  • Lack of efficient healthcare technology may hinder the non-hodgkin lymphoma therapeutics market’s revenue.
  • High cost of approved therapies - The prevalence of various blood malignancies, including lymphomas, has sharply increased, and these trends have also been seen in a number of developing nations. The high cost of some medicines, like immunotherapies, is one of the main obstacles to the expansion of the non-Hodgkin lymphoma therapeutics market.

This drastically limits the number of patients receiving complex and advanced care, and a sizable fraction of lymphoma patients are not receiving any treatment at all. Patients frequently cannot take advantage of these cutting-edge treatment choices, which frequently lead to superior clinical outcomes, because of inadequate payment plans and special considerations from the local governments.

Non-Hodgkin Lymphoma Therapeutics Market Size and Forecast:

Report Attribute Details

Base Year

2025

Forecast Period

2026-2035

CAGR

7.5%

Base Year Market Size (2025)

USD 11.13 billion

Forecast Year Market Size (2035)

USD 22.94 billion

Regional Scope

  • North America (U.S. and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, Malaysia, Australia, South Korea, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC, North Africa, South Africa, Rest of the Middle East and Africa)
Access Detailed Forecasts & Data-Driven Insights: Request Free Sample PDF

Non-Hodgkin Lymphoma Therapeutics Market Segmentation:

Type of Therapy Segment Analysis

The chemotherapy segment in the non-Hodgkin lymphoma therapeutics market is estimated to gain the largest revenue share of about 50% in the year 2035. Chemotherapy is a highly effective treatment for cancer since it stops the cancer cells from spreading more and increasingly widely. It is the most used cancer treatment, working to stop the growth of tumors and eliminate cancer cells. Furthermore, chemotherapy continues to be a mainstay since it works for a wide range of NHL subtypes, despite the advent of new therapies.

The fact that healthcare practitioners are familiar with it and its well-established protocols add to its ongoing demand. Furthermore, chemotherapy is frequently a financially advantageous course of treatment in areas with limited resources. In light of these aspects non-hodgkin lymphoma market is predicted to expand in this segment.

Distribution Channel Segment Analysis

The hospital pharmacies segment is expected to hold 50% share of the global non-Hodgkin lymphoma therapeutics market by 2035. The non-hodgkin lymphoma therapies market is dominated by the hospital pharmacy segment for a number of reasons. Major cancer treatment facilities include hospitals, which offer complete care, including diagnosis, therapy, and follow-up.

The efficient distribution and administration of several medicines are made possible by this focused strategy. Hospitals are also equipped with the facilities needed to handle and store specialized treatments like targeted therapies and chemotherapy. Further, owing to rising number of hospitals the non-hodgkin lymphoma therapeutics market will flourish. The overall number of hospitals globally as of 2021 is estimated to be over 164,000.

Our in-depth analysis of the global non-Hodgkin lymphoma therapeutics market includes the following segments:

          Type of Therapy
  • Chemotherapy
  • Radiation Therapy
  • Target Therapy

          Cell Type
  • B-Cell Lymphoma
  • T-Cell Lymphoma

          Distribution Channel
  • Retail Pharmacies & Drug Stores
  • Hospital Pharmacies
  • Online Pharmacies
Vishnu Nair
Vishnu Nair
Head - Global Business Development

Customize this report to your requirements — connect with our consultant for personalized insights and options.

Non-Hodgkin Lymphoma Therapeutics Market Regional Analysis:

North American Market Insights

Non-hodgkin lymphoma therapeutics market in the North America industry is likely to account for largest revenue share of 30% by 2035. This growth is set to be dominated by growing advancement and adoption of latest technology such as AI. For instance, in the areas of radiology, neurology, and pathology, the Food & Drug Administration (FDA) in the United States will have assessed and authorized over 500 medical AI devices by 2023.

Artificial intelligence (AI) has become so popular in the last few years that a lot of money has been spent on its development and commercialization in the medical industry. Furthermore, there has been launch of various well-regulated framework which has influenced the launch of various treatment options in the region. Also, since the healthcare sector is one of the most regulated in the US, healthcare compliance is an important and rapidly expanding field within the sector. Hence, all these factors are set to dominate the non-hodgkin lymphoma therapeutics market expansion in this region. 

APAC Market Insights

The Asia Pacific non-Hodgkin lymphoma therapeutics market is also estimated to rise over the coming years.  The major element to encourage the growth of the market in this region is rising demand for generic manufacturers. Furthermore, generic drugs are considered to be most affordable.

Hence, with the availability of low-income group the market demand for generic drug is more in this region. Further, the quality of these drugs is same of that branded drugs which is why the demand for it is high. As a result, the rising need for generic drug the market for non-hodgkin lymphoma therapeutics is also set to rise in this region. 

Non-Hodgkin Lymphoma Therapeutics Market Share
Get Strategic Analysis by Region Now: Request Free Sample PDF

Non-Hodgkin Lymphoma Therapeutics Market Players:

    • AbbVie, Inc.
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Teva Pharmaceutical Industries Ltd.
    • Sanofi
    • Pfizer Inc.
    • GSK plc.  
    • Novartis AG
    • Bayer AG
    • Bausch Health Companies Inc.
    • Sun Pharmaceutical Industries Ltd.
    • Aurobindo Pharma
    • SIRPant Immunotherapeutics Inc.

Recent Developments

  • SIRPant-M's investigational new drug (IND) application got FDA approval in May 2023 after reviewing preclinical data that indicated the medication was effective against a range of solid tumours as well as hematologic tumours.
  • AbbVie announced that EPKINLYTM (epcoritamab-bysp), the first and only T-cell engaging bispecific antibody, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with high-grade B-cell lymphoma (HGBL) and diffuse large B-cell lymphoma (DLBCL) that have undergone two or more lines of systemic therapy and are relapsed or refractory (R/R).
  • Report ID: 5584
  • Published Date: Sep 16, 2025
  • Report Format: PDF, PPT
  • Get detailed insights on specific segments/region
  • Inquire about report customization for your industry
  • Learn about our special pricing for startups
  • Request a demo of the report’s key findings
  • Understand the report’s forecasting methodology
  • Inquire about post-purchase support and updates
  • Ask About Company-Level Intelligence Additions

Have specific data needs or budget constraints?

customer-service Inquiry Before Buying

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of non-hodgkin lymphoma therapeutics is assessed at USD 11.88 billion.

The global non-hodgkin lymphoma therapeutics market size surpassed USD 11.13 billion in 2025 and is projected to witness a CAGR of more than 7.5%, crossing USD 22.94 billion revenue by 2035.

North America non-hodgkin lymphoma therapeutics market will hold more than 30% share by 2035, fueled by adoption of AI and well-regulated frameworks in healthcare.

Key players in the market include Roche Holding AG, Bristol-Myers Squibb Company, Novartis AG, Pfizer Inc., Merck & Co., Inc., Gilead Sciences, Inc., Amgen Inc., Celgene Corporation (Bristol-Myers Squibb), AbbVie Inc., Takeda Pharmaceutical Company Limited.

Non-Hodgkin Lymphoma Therapeutics Market Report Scope

GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

Connect with our Expert

Radhika Pawar
Radhika Pawar
Senior Research Analyst
Inquiry Before Buying Request Free Sample PDF

Copyright @ 2025 Research Nester. All Rights Reserved.

footer-bottom-logos